Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 811
interventional 758
Observational 47
Registry 6

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 412
Biological 79
Biological|Drug 55
Drug|Other 32
Biological|Drug|Other 31
Drug|Procedure 19
Biological|Other 14
Drug|Other|Procedure|Radiation 8
Drug|Radiation 8
Other 8
Drug|placebo 7
Biological|Drug|Other|Procedure 6
Biological|Drug|Other|Procedure|Radiation 6
Biological|Drug|Procedure|Radiation 6
Biological|Other|Procedure 5
Biological|Drug|Radiation 4
Drug|Genetic 4
Drug|Procedure|Radiation 4
Radiation 4
Biological|Drug|Other|Radiation 3
Biological|Drug|Procedure 3
Drug|Genetic|Other 3
Drug|Other|Procedure 3
Procedure 3
Biological|Drug|Genetic 2
Biological|Drug|Genetic|Other 2
Biological|Procedure 2
Dietary Supplement|Other 2
Other|Procedure 2
Procedure|Radiation 2
Biological|Device|Drug|Procedure|Radiation 1
Biological|Dietary Supplement|Drug|Other|placebo 1
Biological|Drug|Genetic|Other|Procedure 1
Biological|Genetic|Other 1
Biological|Genetic|Other|Procedure 1
Biological|Procedure|Radiation 1
Biological|Radiation 1
Combination Product 1
Diagnostic Test|Drug|Procedure 1
Dietary Supplement|Drug 1
Drug|Genetic|Other|Procedure|Radiation 1
Drug|Genetic|Procedure 1
Drug|Genetic|Procedure|Radiation 1
Drug|Other|placebo 1
Drug|Other|placebo|Procedure 1
Drug|Other|Radiation 1
Drug|placebo|Procedure 1
Genetic 1
Other|Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 364
China 86
NA 21
France 18
Japan 18
Korea, Republic of 16
United Kingdom 15
Germany 11
Italy 11
Belgium|France 8
Canada 7
United States|Canada 7
Spain 6
United States|United Kingdom 5
Australia 4
Switzerland 4
United States|Italy 4
Belgium|France|Switzerland 3
Singapore 3
United States|France 3
United States|Germany|Italy 3
Israel 2
Italy|Switzerland 2
Russian Federation 2
Sweden 2
Taiwan 2
United States|Australia|Italy 2
United States|Canada|France|Netherlands 2
United States|France|Germany|Spain 2
United States|Spain 2
Algeria|Argentina|Belgium|Brazil|Bulgaria|Canada|Colombia|Finland|France|Greece|Ireland|Israel|Italy|Netherlands|Peru|Poland|Portugal|Russian Federation|Saudi Arabia|Serbia|South Africa|Spain|Thailand|Turkey|Ukraine|United Kingdom|Venezuela 1
Argentina|Brazil|Colombia|India|Indonesia|Iran, Islamic Republic of|Malaysia|Mexico|Paraguay|Philippines|Russian Federation|South Africa 1
Australia|Austria|Belgium|France|Israel|Poland|Portugal|Spain|Switzerland 1
Australia|Austria|Bosnia and Herzegovina|Brazil|Bulgaria|China|Croatia|Czech Republic|Estonia|Hong Kong|Israel|Latvia|Macedonia, The Former Yugoslav Republic of|Malaysia|Mexico|Peru|Romania|Russian Federation|Serbia|Slovakia|Slovenia|South Africa|Sweden|Taiwan|Thailand|Turkey 1
Australia|Belgium|Canada|Denmark|France|Germany|Italy|Korea, Republic of|Singapore|United Kingdom 1
Australia|Belgium|Denmark|Italy|Spain 1
Australia|France|Germany|Hungary|Korea, Republic of|Poland|Singapore|United Kingdom 1
Australia|United States|Belgium|Canada|China|Czechia|France|Ireland|Israel|Italy|Japan|Korea, Republic of|Netherlands|New Zealand|Poland|Portugal|Puerto Rico|Russian Federation|Spain|Switzerland|Taiwan|Turkey 1
Austria 1
Austria|Czechia|Denmark|Finland|Germany|Norway|Sweden|Switzerland 1
Austria|France|Norway 1
Austria|Italy|Switzerland 1
Belgium 1
Belgium|Canada|China|France|Hungary|Italy|Netherlands|Poland|Spain|United Kingdom 1
Belgium|Canada|United States|Australia|France|Germany|Italy|Netherlands|Singapore|Spain|Sweden|United Kingdom 1
Belgium|Denmark|Italy|Spain|United Kingdom 1
Belgium|Netherlands 1
Bosnia and Herzegovina|Croatia|Georgia|Moldova, Republic of|Poland|Serbia|Ukraine 1
Czech Republic 1
Czech Republic|France|Germany|Italy|Netherlands|Poland|Sweden|Switzerland|United Kingdom 1
Czechia|Italy|Netherlands|United Kingdom 1
Denmark|Finland|Norway|Sweden 1
Denmark|Netherlands|Spain|United Kingdom 1
Denmark|Sweden 1
France|Italy 1
France|Italy|Poland|Taiwan|Ukraine|Germany|United States|Australia|Canada|United Kingdom 1
Germany|Italy|Spain 1
Germany|Netherlands|United Kingdom 1
Germany|United States|Belgium|France|Spain|Switzerland|United Kingdom 1
Hong Kong 1
Hungary|Argentina|Australia|Austria|Brazil|Canada|Chile|Colombia|Croatia|Denmark|Dominican Republic|Egypt|El Salvador|Germany|Guatemala|Hong Kong|Indonesia|Italy|Korea, Republic of|Malaysia|Netherlands|New Zealand|Panama|Peru|Philippines|Portugal|Romania|Sweden|Taiwan|Thailand|Turkey|Vietnam 1
India 1
Italy|Poland|United Kingdom 1
Italy|United States|Czechia|Japan|Korea, Republic of|Singapore 1
Japan|United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Chile|China|Colombia|France|Germany|Greece|Hong Kong|Hungary|Ireland|Italy|Korea, Republic of|Lithuania|Malaysia|Mexico|New Zealand|Philippines|Poland|Portugal|Romania|Russian Federation|Singapore|Slovakia|South Africa|Spain|Taiwan|Thailand|Turkey|Ukraine|Vietnam 1
Japan|United States|Argentina|Austria|Belgium|China|Czech Republic|Denmark|Estonia|Finland|Germany|Greece|Hungary|India|Ireland|Israel|Korea, Republic of|Netherlands|Norway|Poland|Russian Federation|Singapore|Spain|Sweden|Thailand|United Kingdom 1
Korea, Republic of|Singapore 1
Malawi 1
Mexico 1
Netherlands 1
New Zealand 1
Poland 1
Switzerland|United Kingdom 1
Thailand 1
Turkey|Ukraine|Brazil|United States|Argentina|Australia|Belgium|Canada|China|Czechia|Denmark|Finland|France|Germany|Hungary|Israel|Japan|Korea, Republic of|Mexico|Netherlands|Norway|Poland|Russian Federation|Spain|Sweden|Taiwan|United Kingdom 1
United States|Argentina|Australia|Austria|Brazil|Canada|China|Colombia|Czechia|Egypt|France|Germany|Greece|Hong Kong|Hungary|Israel|Italy|Japan|Korea, Republic of|Lebanon|Mexico|New Zealand|Norway|Peru|Poland|Russian Federation|Saudi Arabia|Singapore|Slovakia|Spain|Switzerland|Thailand|Turkey|Venezuela 1
United States|Argentina|Australia|Belgium|Brazil|Canada|China|Colombia|Czechia|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Russian Federation|Spain|Sweden|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|China|Cyprus|Czech Republic|Finland|France|Germany|Greece|Hungary|India|Israel|Italy|Korea, Republic of|Mexico|New Zealand|Poland|Portugal|Puerto Rico|Romania|Russian Federation|Slovakia|South Africa|Spain|Sweden|Thailand|Ukraine|United Kingdom 1
United States|Argentina|Canada|China|Czechia|Germany|Italy|Norway|Poland|Portugal|Sweden|Switzerland|Ukraine|United Kingdom 1
United States|Australia 1
United States|Australia|Austria|Belgium|Brazil|Canada|China|Czechia|France|Germany|Hong Kong|Israel|Italy|Japan|Korea, Republic of|New Zealand|Poland|Russian Federation|Spain|Switzerland|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Austria|Belgium|Bulgaria|Canada|France|Germany|Greece|Hungary|India|Israel|Italy|Netherlands|New Zealand|Poland|Serbia|Spain|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|France|Germany|Israel|Italy|Netherlands|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Austria|Canada|Croatia|Czechia|Finland|France|Germany|Hungary|Israel|Italy|Korea, Republic of|New Zealand|Poland|Portugal|Romania|Serbia|Singapore|Spain|Taiwan|Turkey|United Kingdom 1
United States|Australia|Austria|Canada|Czechia|France|Hungary|Italy|Netherlands|Spain 1
United States|Australia|Austria|Canada|France|Germany|Italy|Japan|Netherlands|Norway 1
United States|Australia|Austria|Czechia|France|Italy|Spain|Sweden|United Kingdom 1
United States|Australia|Austria|France|Germany|Hong Kong|Italy|Japan|Netherlands|Norway|Singapore|Spain|Switzerland 1
United States|Australia|Belgium|Canada|Czechia|Denmark|Finland|France|Italy|New Zealand|Poland|Spain|Taiwan 1
United States|Australia|Belgium|Canada|Czechia|France|Greece|Israel|Italy|New Zealand|Poland|Russian Federation|Spain|Sweden|Turkey 1
United States|Australia|Belgium|Canada|Czechia|France|Italy|Korea, Republic of|Poland|Spain|United Kingdom 1
United States|Australia|Belgium|Canada|Italy|Puerto Rico|Spain|United Kingdom 1
United States|Australia|Belgium|Czechia|Finland|Germany|Israel|Sweden|Switzerland|United Kingdom 1
United States|Australia|Belgium|Italy|Korea, Republic of|Poland|Spain|United Kingdom 1
United States|Australia|Canada|Czechia|France|Germany|Hungary|Italy|Korea, Republic of|Netherlands|Spain|Turkey|United Kingdom 1
United States|Australia|Canada|Denmark|France|Germany|Italy|Spain|United Kingdom 1
United States|Australia|Canada|France 1
United States|Australia|Canada|France|Italy|Korea, Republic of|Poland|Singapore|Spain|Taiwan|United Kingdom 1
United States|Australia|Canada|Germany|Israel|Italy 1
United States|Australia|Denmark|Spain 1
United States|Australia|France|Germany|Netherlands|Spain 1
United States|Australia|France|Poland 1
United States|Austria|Belgium|Bulgaria|Czechia|Denmark|France|Germany|Hungary|Italy|Poland|Romania|Russian Federation|Slovakia|Spain|Ukraine|United Kingdom 1
United States|Austria|Belgium|Czechia|Germany|Portugal 1
United States|Austria|Canada|Germany 1
United States|Austria|Denmark|Estonia|United Kingdom 1
United States|Austria|Korea, Republic of|Spain 1
United States|Belgium|Brazil|Bulgaria|Canada|Czechia|France|Germany|Hungary|Italy|Korea, Republic of|Netherlands|Poland|Romania|Russian Federation|Spain|Sweden|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Belgium|Bulgaria|Czechia|Hungary|Italy|Poland|Switzerland|Ukraine 1
United States|Belgium|Canada|France|Hong Kong|Japan|Korea, Republic of|Singapore|United Kingdom 1
United States|Belgium|Canada|Germany|Korea, Republic of 1
United States|Belgium|Canada|Spain 1
United States|Belgium|Czechia|France|Germany|Hungary|Italy|Poland|Spain|United Kingdom 1
United States|Belgium|Czechia|Israel|Italy|Poland|Spain|Turkey|United Kingdom 1
United States|Belgium|France|Germany|Italy|Japan|Netherlands|Spain|Sweden|Switzerland|United Kingdom 1
United States|Belgium|France|Germany|Italy|Korea, Republic of|Spain|Turkey 1
United States|Belgium|France|Italy 1
United States|Belgium|France|Italy|Netherlands|Spain 1
United States|Belgium|Germany|United Kingdom 1
United States|Belgium|Israel 1
United States|Canada|Czechia|France|Germany|Hungary|Israel|Poland|Russian Federation|Spain|Turkey 1
United States|Canada|France|Germany|Israel|Netherlands 1
United States|Canada|France|Germany|Italy 1
United States|Canada|France|Germany|Italy|Netherlands 1
United States|Canada|France|Germany|Spain|United Kingdom 1
United States|Canada|France|Italy 1
United States|Canada|Georgia|Moldova, Republic of|Poland|Spain|Ukraine 1
United States|China 1
United States|Denmark 1
United States|Egypt|Singapore 1
United States|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Taiwan 1
United States|France|Germany|Italy|Poland|United Kingdom 1
United States|France|Germany|Italy|United Kingdom 1
United States|France|Germany|Korea, Republic of|Singapore|United Kingdom 1
United States|France|Ireland|United Kingdom 1
United States|France|Korea, Republic of 1
United States|France|Switzerland 1
United States|France|United Kingdom 1
United States|Germany 1
United States|Germany|Ireland|Spain|United Kingdom 1
United States|Germany|Italy|Spain|United Kingdom 1
United States|Germany|Poland 1
United States|India|Israel 1
United States|Israel|Poland|Spain 1
United States|Italy|Spain 1
United States|Italy|Spain|United Kingdom 1
United States|Italy|Switzerland|United Kingdom 1
United States|Korea, Republic of 1
United States|Poland 1
United States|Poland|Spain|Sweden 1
United States|Saudi Arabia 1
United States|Spain|United Kingdom 1
United States|Switzerland 1

Sites per Study

Site_count Study_Count
1 347
2 46
3 34
4 20
5 25
6 24
7 17
8 9
9 13
10 16
11 23
12 8
13 9
14 11
15 8
16 6
17 7
18 4
19 6
20 7
21 6
22 5
23 5
24 5
25 6
27 2
28 5
29 1
30 4
31 3
32 3
33 1
34 1
35 2
36 4
37 1
38 1
39 1
40 3
41 4
42 1
45 2
46 2
47 1
51 1
52 2
53 2
56 1
57 2
60 1
62 2
67 1
70 1
75 1
77 1
83 1
84 1
85 1
87 1
91 1
92 1
97 1
108 1
109 1
126 2
131 2
151 1
157 1
158 1
162 1
164 1
165 1
173 1
186 1
190 1
192 1
202 1
206 2
240 1
246 1
257 1
273 1
282 1
338 1
510 1
551 1

Phase

Phase Study_Count
Phase 2 275
Phase 1 241
Phase 1/Phase 2 131
Phase 3 51
N/A 32
Early Phase 1 12
Phase 2/Phase 3 10
Phase 4 6

Number of Arms

Number_of_Arms Count_of_Studies
1 477
2 142
3 38
4 23
5 13
6 8
7 2
8 5
10 3
11 1
12 1
13 1
NA 44

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 4.00000 5.0 2.00000 5.00000 5.00000 20.00 29.0000 32.0000
1st Qu. 8.50000 37.5 18.00000 30.00000 35.00000 125.25 172.0000 52.5000
Median 15.50000 66.0 32.50000 48.50000 54.00000 250.00 359.0000 130.0000
Mean 16.41667 130.5 50.70833 79.76923 69.29091 234.70 430.4706 188.6667
3rd Qu. 21.50000 136.5 59.25000 91.75000 78.50000 312.00 650.0000 267.5000
Max. 33.00000 713.0 700.00000 422.00000 586.00000 450.00 1337.0000 500.0000

Trial Group Type

group_type Group_Count
Experimental 1070
Active Comparator 91
NA 44
Other 26
Placebo Comparator 7
No Intervention 5
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 521
Parallel Assignment 174
Sequential Assignment 47
NA 12
Crossover Assignment 2
Factorial Assignment 2

Primary Purpose

primary_purpose Study_Count
Treatment 727
Diagnostic 11
Supportive Care 10
Prevention 5
Basic Science 4
Screening 1

Observational Studies

Studies by Country

Country Study_Count
Korea, Republic of 8
United States 8
France 6
NA 5
China 4
United Kingdom 2
Austria|Brazil|France|Italy|Portugal|Ukraine 1
Brazil|Italy 1
Denmark 1
Germany 1
Italy 1
Italy|Spain|Switzerland|United Kingdom 1
Japan 1
Netherlands 1
Russian Federation 1
Serbia 1
Spain 1
Switzerland 1
United States|Australia|Canada|Puerto Rico 1
United States|France|Italy|Spain 1

Sites per Study

Site_count Study_Count
1 29
2 2
4 1
5 1
12 1
15 1
16 1
17 1
20 1
24 1
35 1
39 1
48 1
56 1
57 1
61 1
111 1
130 1

Enrollment Metrics

Measure Observational
Min 8.0000
1st Qu 94.0000
Median 154.0000
Mean 405.5532
3rd Qu 383.5000
Max 3000.0000

Observation Model

observational_model Study_Count
Cohort 30
Case-Only 6
Other 5
Case Control 2
Case-Control 1
Case-Crossover 1
Family-Based 1
NA 1

Time Perspective

time_perspective Study_Count
Prospective 27
Retrospective 16
Cross-Sectional 3
NA 1

Registries

Studies by Country

Country Study_Count
Korea, Republic of 2
China 1
Denmark 1
Spain 1
Taiwan 1

Sites per Study

Site_count Study_Count
1 4
14 1
24 1

Enrollment Metrics

Measure Registries
Min 75.0000
1st Qu 125.0000
Median 350.0000
Mean 645.8333
3rd Qu 875.0000
Max 2000.0000

Registry Model

observational_model Study_Count
Cohort 5
Case-Only 1

Time Perspective

time_perspective Study_Count
Prospective 5
Other 1

Follow-up

target_duration Study_Count
2 Years 2
5 Years 2
10 Years 1
36 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT04435743 Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin’s Lymphomas https://ClinicalTrials.gov/show/NCT04435743 Recruiting Ruijin Hospital 2022-12-31
NCT03378947 EBV-associated Diffuse Large B Cell Lymphoma https://ClinicalTrials.gov/show/NCT03378947 Completed Hospices Civils de Lyon 2018-01-15
NCT03375619 Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells https://ClinicalTrials.gov/show/NCT03375619 Recruiting Medical College of Wisconsin 2020-08-01
NCT03280394 Liquid Biopsy in Mature B-cell Tumors https://ClinicalTrials.gov/show/NCT03280394 Recruiting Oncology Institute of Southern Switzerland 2027-12-31
NCT03211702 Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2) https://ClinicalTrials.gov/show/NCT03211702 Active, not recruiting Chonbuk National University Hospital 2018-04-30
NCT03104478 Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL) https://ClinicalTrials.gov/show/NCT03104478 Recruiting The Lymphoma Academic Research Organisation 2020-12-31
NCT03000192 HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life https://ClinicalTrials.gov/show/NCT03000192 Active, not recruiting University Hospital Southampton NHS Foundation Trust 2020-12-31
NCT02708732 Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL) https://ClinicalTrials.gov/show/NCT02708732 Completed Hoffmann-La Roche 2016-10-31
NCT02633111 DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas https://ClinicalTrials.gov/show/NCT02633111 Recruiting Memorial Sloan Kettering Cancer Center 2021-10-31
NCT02555267 Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma https://ClinicalTrials.gov/show/NCT02555267 Active, not recruiting Chonbuk National University Hospital 2017-07-31
NCT02486952 MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT02486952 Completed Hoffmann-La Roche 2011-01-31
NCT02354846 An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With Tenofovir in HBsAg-positive Patients With Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy (SPEED Study) https://ClinicalTrials.gov/show/NCT02354846 Recruiting Yonsei University 2021-03-31
NCT02240316 An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice https://ClinicalTrials.gov/show/NCT02240316 Completed Hoffmann-La Roche 2019-07-22
NCT02072967 Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT02072967 Completed Astellas Pharma Inc 2015-10-31
NCT02060435 Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma https://ClinicalTrials.gov/show/NCT02060435 Completed Samsung Medical Center 2013-12-31
NCT01809600 Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt’s or Burkitt-like Lymphoma in Adults https://ClinicalTrials.gov/show/NCT01809600 Completed Gachon University Gil Medical Center 2014-03-31
NCT01660776 BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology https://ClinicalTrials.gov/show/NCT01660776 Completed Rennes University Hospital 2017-10-02
NCT01606605 Treatment Resistance Related With Gene Expression Profile of Diffuse Large B-cell Lymphoma https://ClinicalTrials.gov/show/NCT01606605 Completed Samsung Medical Center 2012-12-31
NCT01563861 S9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01563861 Completed Southwest Oncology Group 2008-06-01
NCT01478269 Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen https://ClinicalTrials.gov/show/NCT01478269 Completed Fondazione Italiana Linfomi ONLUS 2011-05-31
NCT01369784 Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma https://ClinicalTrials.gov/show/NCT01369784 Completed Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 2011-03-31
NCT01340443 An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01340443 Completed Hoffmann-La Roche 2016-07-15
NCT04423549 Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell Lymphoma https://ClinicalTrials.gov/show/NCT04423549 Recruiting Sun Yat-sen University 2021-06-30
NCT04354402 Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL https://ClinicalTrials.gov/show/NCT04354402 Enrolling by invitation SymBio Pharmaceuticals 2020-12-31
NCT04317313 Prediction of Outcome Using Pretreatment 18F-FDG PET/CT Radiomic Features in Diffuse Large B-cell Lymphoma https://ClinicalTrials.gov/show/NCT04317313 Completed Second Affiliated Hospital, School of Medicine, Zhejiang University 2018-09-30
NCT04300998 Study of CAR-T Therapy in Older Patients https://ClinicalTrials.gov/show/NCT04300998 Recruiting Memorial Sloan Kettering Cancer Center 2021-03-04
NCT04150328 Lenalidomide Monotherapy in R/R DLBCL https://ClinicalTrials.gov/show/NCT04150328 Recruiting MorphoSys AG 2019-08-29
NCT04139252 A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients https://ClinicalTrials.gov/show/NCT04139252 Recruiting Stichting Hemato-Oncologie voor Volwassenen Nederland 2022-06-30
NCT04088422 Cell Free DNA in Mature B-cell Lymphoma https://ClinicalTrials.gov/show/NCT04088422 Recruiting Ruijin Hospital 2024-04-30
NCT03977623 Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression https://ClinicalTrials.gov/show/NCT03977623 Recruiting Samsung Medical Center 2022-02-28
NCT03797170 Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma https://ClinicalTrials.gov/show/NCT03797170 Recruiting University of Bologna 2020-07-20
NCT03681938 Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission? https://ClinicalTrials.gov/show/NCT03681938 Active, not recruiting Institut Paoli-Calmettes 2019-07-28
NCT03664336 Refractory Diffuse Large B-cell Lymphoma https://ClinicalTrials.gov/show/NCT03664336 Completed Hospices Civils de Lyon 2017-07-31
NCT01266668 The Impact of Rituximab in Patients With Primary Breast Diffuse Large B Cell Lymphoma (DLBCL) https://ClinicalTrials.gov/show/NCT01266668 Completed Chonbuk National University Hospital 2011-05-31
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT01131208 Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab https://ClinicalTrials.gov/show/NCT01131208 Completed Eastern Cooperative Oncology Group 2010-08-21
NCT01000753 Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01000753 Active, not recruiting Children’s Oncology Group 2007-06-01
NCT00981097 Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00981097 Completed AIDS Malignancy Consortium 2013-06-30
NCT00944567 A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT00944567 Completed International Extranodal Lymphoma Study Group (IELSG) 2011-05-31
NCT00898157 Study of Biomarkers Using Tissue Samples From Older Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab on Clinical Trial ECOG-E4494 https://ClinicalTrials.gov/show/NCT00898157 Completed Eastern Cooperative Oncology Group 2008-09-24
NCT04183569 Identification Predictive Markers of Immunochemotherapy Response to the Primary Cutaneous Diffuse Large B Cell Lymphoma https://ClinicalTrials.gov/show/NCT04183569 Active, not recruiting University Hospital, Bordeaux 2020-05-01
NCT02904577 Indolent Non Follicular Lymphomas Prognostic Project https://ClinicalTrials.gov/show/NCT02904577 Active, not recruiting Fondazione Italiana Linfomi ONLUS 2024-09-30
NCT02992223 Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT https://ClinicalTrials.gov/show/NCT02992223 Completed Azienda Ospedaliera Città della Salute e della Scienza di Torino 2015-07-31
NCT00754117 Early Response Assessment in Diffuse Large B-Cell Lymphoma (DLCL) Patients by 18-fluoro-2-deoxyglycose Positron Emission Tomography (FDG-PET) https://ClinicalTrials.gov/show/NCT00754117 Completed Weill Medical College of Cornell University 2010-12-31
NCT00626496 Family Study of Lymphoproliferative Disorders https://ClinicalTrials.gov/show/NCT00626496 Recruiting Mayo Clinic 2025-12-31
NCT00487513 Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials https://ClinicalTrials.gov/show/NCT00487513 Completed Dana-Farber Cancer Institute 2017-01-31
NCT00286832 Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV https://ClinicalTrials.gov/show/NCT00286832 Completed Copenhagen University Hospital at Herlev 2011-01-31

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02732236 Marginal Zone Lymphoma Cohort in Korea https://ClinicalTrials.gov/show/NCT02732236 Recruiting Dong-A University Hospital 2020-02-29
NCT02474550 Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma https://ClinicalTrials.gov/show/NCT02474550 Recruiting Ajou University School of Medicine 2018-12-31
NCT04158128 The Clinical Implications of Immune Checkpoint Pathways in PCNSL https://ClinicalTrials.gov/show/NCT04158128 Recruiting National Taiwan University Hospital 2019-12-31
NCT04112238 ctDNA and Metabolites in CSF as Early Biomarkers of Secondary CNS Involvement in Diffuse Large B-cell Lymphoma https://ClinicalTrials.gov/show/NCT04112238 Recruiting Herlev Hospital 2023-06-30
NCT03715296 Lenalidomide Based Immunotherapy in the Treatment of DLBCL https://ClinicalTrials.gov/show/NCT03715296 Recruiting Ruijin Hospital 2020-09-15
NCT03646422 AEDV Registry of Primary Cutaneous Lymphoma https://ClinicalTrials.gov/show/NCT03646422 Recruiting Fundación Academia Española de Dermatología 2025-01-01